Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Lilly’s Taltz leads to durable improvement in axial spondyloarthritis in Phase 3 study

By Brian Buntz | June 2, 2021

Eli LillyEli Lilly and Company (NYSE:LLY) has announced that recent Phase 3 data suggest Taltz (ixekizumab) was effective in the long-term management of axial spondyloarthritis (axSpA).

Taltz, an interleukin-17A antagonist, is currently indicated for plaque psoriasis, psoriatic arthritis and active ankylosing spondylitis.

In the COAST-Y study, Taltz demonstrated long-term improvements in patients’ symptoms with the two subtypes of axSpA. The first, known as radiographic axSpA (r-axSpA), involves defined structural damage of the sacroiliac joints evident on x-ray films. The second type, known as non-radiographic axSpA (nr-axSpA), lacks such structural damage.

The former can lead to substantial reductions in quality of life. “If left uncontrolled, individuals living with active radiographic axSpA can experience severe, chronic pain and structural damage in the spine that can lead to fusion of the spine and loss of mobility,” explained Dr. Walter P. Maksymowych, professor of medicine at the University of Alberta, who was the senior author of this analysis. “Most patients treated with ixekizumab did not show structural damage progression at two years, and the degree of progression was small,” he said in prepared remarks.

In the COAST-Y, the researchers used the Assessment of SpondyloArthritis International Society (ASAS) diagnostic criteria to assess improvements in clinical trials. The criteria include the following domains: patient global assessment, pain assessment, function and inflammation. ASAS40 response requires an overall improvement of at least 40% and an improvement across three of the four domains.

In the COAST-Y study, 56.7% of patients who received 80-mg doses of Taltz every four weeks for two years achieved an Assessment of SpondyloArthritis international Society response (ASAS40) of 40%.


Filed Under: Rheumatology
Tagged With: ASAS, ASAS40, Assessment of SpondyloArthritis International Society, axial spondyloarthritis, axSpA, Eli Lilly, ixekizumab, Taltz
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Rosnilimab phase 2b trial shows promise in treating RA
rosnilimab
PD-1 agonists show promise in treating rheumatoid arthritis by restoring immune balance 
Zai Lab
Zai Lab’s unified approach to tackling cancer, autoimmune, and neurological diseases
Johnson & Johnson
How a J&J exec found her calling in autoantibody drug development
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE